We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer.
We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. Our commercial success depends on creating innovative new products and making these accessible to as many people who need them as possible. By achieving this, we will be able to grow our business and provide benefits to patients, consumers, society, our employees and our shareholders.
With our headquarters in the UK, we have a wide geographical reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally.
Research is vitally important to the success of our business, and we spent just under £4 billion in 2012 in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.
Our pharmaceuticals business researches, develops and makes available medicines that treat a variety of serious and chronic diseases. We have medicines available or in development in a wide range of areas including:
Our vaccine business is one of the largest in the world, with nearly 900 million doses distributed to 170 countries in 2012. We produce paediatric and adult vaccines to prevent a range of infectious diseases including:
Through our consumer healthcare business, we market a range of consumer health products based on scientific innovation. We have leading positions in four main categories:
In these areas we have a number of well known brands including Sensodyne, Panadol and Horlicks.
Copyright 1995 - 2010 . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc)
published in this site belongs to China Daily Information Co (CDIC).
Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.